Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Expenses (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Accumulated Expenses history runs 14 years deep, the most recent figure standing at $38.5 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 30.25% year-over-year to $38.5 million in Q1 2026; TTM through Mar 2026 was $38.5 million, a 30.25% increase from a year earlier, with the FY2025 full-year figure at $62.0 million, up 35.6% from the prior year.
• Accumulated Expenses retreated to $38.5 million in Q1 2026 per VRDN's latest filing, from $62.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $62.0 million in Q4 2025 and bottomed at $11.6 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $24.2 million (2023), against an average of $28.8 million.
• Across the five-year window, Accumulated Expenses retreated 9.43% in 2022 and jumped 89.69% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $18.8 million in 2022, then advanced by 28.05% to $24.1 million in 2023, then soared by 89.69% to $45.7 million in 2024, then surged by 35.6% to $62.0 million in 2025, then slumped by 37.93% to $38.5 million in 2026.
• Per Business Quant, the three latest VRDN Accumulated Expenses figures stand at $38.5 million (Q1 2026), $62.0 million (Q4 2025), and $40.6 million (Q3 2025).